Focus: Pulse Biosciences is a medical device and therapeutic company specializing in nano-pulse stimulation technology across cardiovascular, metabolic, neurological, oncology, and endocrinology indications. The company is publicly traded and maintains a diverse pipeline spanning device-based systems and pharmaceutical interventions.
Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
Best suited for device-engineering or specialized manufacturing roles seeking exposure to emerging nano-pulse technology; limited appeal for traditional pharma R&D or commercial professionals due to thin hiring and data-quality red flags.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pulse Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pulse Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
FDA Aligns on Rocket Pharmaceuticals RP-A501 Phase 2 Trial Design for Danon Disease - The Clinical Trial Vanguard
FDA Aligns on Rocket Pharmaceuticals RP-A501 Phase 2 Trial Design for Danon Disease The Clinical Trial Vanguard
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Investing News Network
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse Vybrance Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Investing News Network
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules - Business Wire
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Business Wire
Is Pulse Biosciences (PLSE) Fully Valued After Its Recent Surge? - simplywall.st
Is Pulse Biosciences (PLSE) Fully Valued After Its Recent Surge? simplywall.st
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Pulse Biosciences (PLSE), Why Is Attention Building Around It? - simplywall.st
Pulse Biosciences (PLSE), Why Is Attention Building Around It? simplywall.st
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
High-Voltage Nanosecond Pulse Field Ablation Using a Compliant Circular Catheter to Treat Atrial Fibrillation: Lesion Durability and One-Year Outcomes.
Is Deficiency in the Electrical Current of Injury a Barrier to Healing in Hard-to-Heal Wounds? A Systematic Review with Implications for the TIMERS Paradigm.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo